International Journal of Breast Cancer / 2013 / Article / Tab 4

Research Article

Use of Cox’s Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response

Table 4

The estimated proportion of cured patients.

HR status Clinical response HER2 status Histological gradeNumber of lymph node metastasesEstimated proportion of cured patients

NegativeSD/PDNegative1 and 2089.3%
1 to 378.2%
≥444.7%
3083.1%
1 to 367.8%
≥432.2%
Positive1 and 2081.7%
1 to 365.8%
≥430.2%
3072.4%
1 to 353.0%
≥420.2%
PRNegative1 and 2087.3%
1 to 374.6%
≥439.8%
3080.1%
1 to 363.4%
≥428.0%
Positive1 and 2078.6%
1 to 361.2%
≥426.2%
3068.3%
1 to 348.1%
≥417.2%
CRNegative1 and 2094.9%
1 to 389.0%
≥464.4%
3091.7%
1 to 382.6%
≥451.6%
Positive1 and 2090.9%
1 to 381.2%
≥449.2%
3085.5%
1 to 371.7%
≥436.3%
PositiveSD/PDNegative1 and 2071.2%
1 to 351.5%
≥419.3%
3059.2%
1 to 338.4%
≥412.3%
Positive1 and 2057.0%
1 to 336.3%
≥411.3%
3043.8%
1 to 325.1%
≥47.0%
PRNegative1 and 2067.0%
1 to 346.6%
≥416.4%
3054.4%
1 to 333.9%
≥410.3%
Positive1 and 2052.1%
1 to 331.8%
≥49.5%
3039.0%
1 to 321.5%
≥45.8%
CRNegative1 and 2084.7%
1 to 370.5%
≥434.9%
3076.5%
1 to 358.4%
≥424.0%
Positive1 and 2074.8%
1 to 356.1%
≥422.3%
3063.6%
1 to 342.9%
≥414.4%

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.